UBS Group
QTTB icon

UBS Group’s Q32 Bio QTTB Stock Holding History

UBS Group’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.73K Sell
270
-13,336
-98% -$63.4K ﹤0.01% 9452
2025
Q4 		$45.2K Buy
13,606
+8,360
+159% +$23.6K ﹤0.01% 7282
2025
Q3 		$10.4K Sell
5,246
-7,330
-58% -$14.1K ﹤0.01% 8545
2025
Q2 		$18.7K Sell
12,576
-20,855
-62% -$35.5K ﹤0.01% 8489
2025
Q1 		$55.2K Sell
33,431
-14,551
-30% -$39.2K ﹤0.01% 7508
2024
Q4 		$165K Buy
47,982
+44,340
+1,217% +$1.4M ﹤0.01% 6575
2024
Q3 		$163K Buy
3,642
+996
+38% +$36.6K ﹤0.01% 6025
2024
Q2 		$47.5K Buy
2,646
+1,706
+181% +$40.8K ﹤0.01% 6729
2024
Q1 		$16K Buy
940
+184
+24% +$2.54K ﹤0.01% 7021
2023
Q4 		$8.27K Sell
756
-47
-6% -$687 ﹤0.01% 7571
2023
Q3 		$16.9K Sell
803
-108
-12% -$2.2K ﹤0.01% 6891
2023
Q2 		$14.5K Buy
911
+285
+46% +$5.12K ﹤0.01% 7011
2023
Q1 		$11.6K Sell
626
-144
-19% -$3.59K ﹤0.01% 7488
2022
Q4 		$17.5K Sell
770
-1,077
-58% -$28.6K ﹤0.01% 7835
2022
Q3 		$54K Sell
1,847
-8,715
-83% -$355K ﹤0.01% 6292
2022
Q2 		$375K Buy
10,562
+9,204
+678% +$314K ﹤0.01% 4480
2022
Q1 		$74K Sell
1,358
-609
-31% -$37.8K ﹤0.01% 6132
2021
Q4 		$129K Buy
1,967
+1,275
+184% +$124K ﹤0.01% 6068
2021
Q3 		$98K Buy
692
+461
+200% +$58.7K ﹤0.01% 5852
2021
Q2 		$30K Sell
231
-5,956
-96% -$743K ﹤0.01% 6947
2021
Q1 		$1.05M Buy
6,187
+365
+6% +$76.9K ﹤0.01% 4199
2020
Q4 		$1.18M Buy
5,822
+628
+12% +$121K ﹤0.01% 3876
2020
Q3 		$1M Buy
+5,194
New +$1.16M ﹤0.01% 3640
2020
Q2 		– Sell
-491
Closed -$137K – 8425
2020
Q1 		$137K Buy
491
+380
+342% +$116K ﹤0.01% 5024
2019
Q4 		$41K Sell
111
-2,595
-96% -$743K ﹤0.01% 6467
2019
Q3 		$882K Buy
2,706
+2,227
+465% +$757K ﹤0.01% 4073
2019
Q2 		$169K Buy
479
+396
+477% +$156K ﹤0.01% 5020
2019
Q1 		$42K Buy
83
+21
+34% +$9.39K ﹤0.01% 5692
2018
Q4 		$25K Sell
62
-105
-63% -$39.7K ﹤0.01% 6619
2018
Q3 		$68K Buy
167
+72
+76% +$24.5K ﹤0.01% 5925
2018
Q2 		$35K Buy
+95
New +$34K ﹤0.01% 6285

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group's QTTB Position: Q1 2026 in Review

UBS Group reduced its Q32 Bio (QTTB) stake by 98% in Q1 2026, selling an estimated $63.4K and leaving 270 shares worth $1.73K. The position accounts for ﹤0.01% of the portfolio, ranked #9452.

UBS Group first reported a position in QTTB in Q2 2018 and has held it in 31 quarters since. The position peaked at $1.18M in Q4 2020. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • UBS Group held 270 shares of Q32 Bio worth $1.73K as of Q1 2026.
  • UBS Group sold 13,336 Q32 Bio shares in Q1 2026, an estimated $63.4K.
  • Q32 Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9452 holding.
  • UBS Group first reported a position in Q32 Bio in Q2 2018 and has held it in 31 quarters since.
  • UBS Group's Q32 Bio position peaked at $1.18M in Q4 2020.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.